Evan Lee Salim
In the rapidly evolving world of telehealth, Hims & Hers Health, Inc. finds itself at a critical strategic crossroads. Following a period of hyper-growth fueled by the meteoric rise of GLP-1 weight-loss medications, the company is now transitioning toward a more sustainable, technology-driven business model. Central to this evolution is an aggressive investment in artificial intelligence, designed to transform the company from a direct-to-consumer pharmacy service into a comprehensive, AI-integrated healthcare platform.
During its first-quarter earnings call, leadership signaled that the company’s future relies on its ability to build an "end-to-end" patient experience. By leveraging specialized AI agents and re-architecting its technological infrastructure, Hims & Hers aims to solve the dual challenge of scaling clinical care while maintaining the personalized, high-touch experience that consumers have come to expect in the digital health era.
The Strategic Shift: Building an AI-Powered Ecosystem
For years, Hims & Hers has been defined by its ability to identify market trends—such as the demand for compounded GLP-1 injections—and capitalize on them with speed. However, as regulatory landscapes shift and the novelty of rapid growth begins to normalize, the company is pivoting toward operational efficiency and platform stickiness.
Chief Technology Officer Mo Elshenawy, who joined the company last year, is the architect of this transition. Under his guidance, the company has assembled a team of roughly 40 specialists dedicated to embedding AI across the entire patient journey. The objective is not merely to automate, but to create a "modular" platform that can adapt to different medical specialties—from dermatology and sexual health to weight management and beyond.
The Role of AI Agents
The company’s current AI strategy is bifurcated into two main prongs:
- Patient-Facing Companions: Designed to provide support, reminders, and context for users navigating their health journeys.
- Provider-Side Tools: AI agents that assist clinicians by summarizing data, drafting responses, and flagging critical patient information, all while keeping the human provider firmly in the loop for final decision-making.
A Chronology of Growth and Legal Friction
To understand the urgency of the company’s AI pivot, one must look at the recent, volatile history of its business model.
- 2024: The GLP-1 Surge: Hims & Hers experienced a banner year, with revenue growing nearly 69%. This growth was largely predicated on the company’s decision to offer compounded GLP-1 injections during a time when brand-name drugs like Ozempic and Wegovy faced severe national shortages.
- Early 2025: Regulatory Headwinds: As the FDA began to address supply chain issues, the legality of compounded medications came under intense scrutiny. Major pharmaceutical incumbents, most notably Novo Nordisk, challenged the necessity and safety of compounded alternatives.
- February 2026: The Legal Conflict: Novo Nordisk filed a lawsuit against Hims & Hers, with company counsel describing the continued sale of compounded GLP-1s as a "complete sham" given that the shortages were largely resolved.
- The Resolution: Facing intense legal pressure and a shifting regulatory environment, Hims & Hers reached a landmark agreement with Novo Nordisk. The telehealth firm agreed to offer branded Wegovy and Ozempic on its platform, effectively ending the litigation and transitioning away from its reliance on compounding.
- Q1 2026: The "New Normal": In its latest earnings report, the company announced revenue of $608.1 million, reflecting a 4% year-over-year growth rate. While this is a significant departure from the 69% growth observed during the height of the compounding craze, it represents a stabilization of the business model.
Supporting Data: By the Numbers
The transition from a "growth-at-all-costs" model to a "platform-first" model is reflected in the company’s recent performance data:
- Revenue Stabilization: The $608.1 million in quarterly revenue underscores that while the explosive growth of 2024 has leveled off, the company retains a massive, active user base.
- GLP-1 Demand: Despite the pivot to branded medications, demand for weight-loss support remains at "near record levels." Within just six weeks of introducing direct access to Novo Nordisk products, Hims & Hers successfully fulfilled more than 125,000 shipments of Wegovy.
- AI Integration: The company’s tech stack has been completely re-architected. Key improvements include a new "no-code" commercial engine and highly configurable clinical workflows. These changes allow the company to launch new specialties and products with unprecedented agility.
Official Perspectives: The Leadership Vision
During the earnings call, CEO Andrew Dudum and CTO Mo Elshenawy articulated a vision where AI is not a peripheral feature, but the core operating system of the company.
"The labs companion and the upcoming weight-loss companion are really the first iteration in what I would expect eventually becomes multiple agents that are supporting each stage of the customer’s journey across every specialty we serve," Dudum explained.
Elshenawy emphasized the technical discipline required for this transition. "Over the past year, we’ve been re-architecting the platform around reusable, modular capabilities," he noted. "We are building a platform that can support greater complexity while also making the customer and provider experience more approachable."
Crucially, leadership remains emphatic about clinical safety. Regarding the AI-assisted provider tools, Elshenawy stated: "We are keeping independent providers responsible for all clinical decision-making. The AI can draft a contextual answer, but the provider still has to review it before it goes live." This "human-in-the-loop" design is a response to both ethical requirements and the need to maintain trust in a healthcare setting.
Implications: What Lies Ahead?
The implications of Hims & Hers’ AI-first strategy are twofold: one for the competitive telehealth market, and one for the future of digital patient care.
1. Competitive Differentiation
By launching tools like "Labs AI"—which interprets complex biomarker results for the average patient—Hims & Hers is attempting to create "stickiness." In a market where competitors can easily replicate pharmaceutical offerings, the user experience becomes the primary moat. If a patient feels supported by an AI companion that proactively manages their health journey, they are less likely to churn to a generic competitor.
2. Clinical Scalability
The "end-to-end" platform approach is a hedge against the limitations of traditional healthcare. By automating administrative tasks and pre-screening clinical data, Hims & Hers allows its network of independent providers to see more patients with higher precision. If the company can successfully deploy AI agents for various conditions without compromising on care, it could significantly lower its customer acquisition costs while increasing lifetime value.
3. Regulatory Guardrails
The company’s heavy emphasis on "guardrails and evaluation frameworks" suggests a company that has learned from its recent legal battles. By embedding compliance directly into the code—ensuring that AI-enabled workflows have clear escalation paths—Hims & Hers is attempting to preempt future regulatory challenges regarding the role of automated systems in medicine.
4. The Weight-Loss Frontier
With the upcoming launch of an AI-driven weight-loss companion, the company is doubling down on the most lucrative segment of its business. The success of this tool will likely serve as a litmus test for the company’s broader AI ambitions. If the tool can successfully drive engagement and outcomes, it validates the shift; if it fails to gain traction, the company may find itself struggling to justify its heavy investment in AI during a period of slower revenue growth.
Conclusion
Hims & Hers is no longer just a digital pharmacy; it is positioning itself as a vertically integrated healthcare technology firm. The transition from the high-growth, high-friction period of compounded GLP-1s to a stable, AI-augmented future is fraught with challenges, yet the company’s recent earnings call suggests a clear, methodical path forward.
By prioritizing modularity, clinical safety, and deeply personalized AI interactions, Hims & Hers is attempting to build a platform that is as resilient as it is innovative. Whether this strategy will lead to the next wave of double-digit growth remains to be seen, but one thing is certain: the future of Hims & Hers will be written in code.
Jia Lissa
Basiran
Nila Kartika Wati
Sagoh
Lina Hope